Introduction:
India is one of the fastest growing pharmaceutical markets
in the world and has a rapidly expanding prevalent population of breast cancer
(CaB) patients. Combined with increasing access to medical care and a
burgeoning middle class with growing economic clout, these factors promise
double-digit growth and significant opportunity for multinational
pharmaceutical companies.
Questions Answered in This Report:
*
India is the second most populous country in the world, with more than
1.1 billion citizens in 2008. The risk of developing CaB is increasing rapidly
in India because of the aging population and the influence of urbanization.
How
will the incidence of CaB change between 2007 and 2017? How will the diagnosis
and drug-treatment rates change in urban and rural regions of India?
*
Like their counterparts in the United States and Europe, Indian
physicians are most influenced by a drug’s safety and efficacy profile when
choosing therapies for their patients. However, cost is a much greater
constraint
on CaB treatment in India than in Western countries.
How are these factors
driving Indian physicians’ prescribing habits? How do physicians choose between
branded Western drugs and Indian-manufactured equivalents for the treatment of
CaB?
*
The Indian CaB market is growing rapidly, with strong,
double-digit annual gains in sales.
What was the size of the CaB market in
2007? How large will the market be in 2012? How do branded Western drugs fare
against Indian competitors? Which drugs will dominate the market by 2012?Scope:
Markets covered: India.
Primary research: 110 physician surveys in Delhi,
Mumbai, Chennai, Bangalore, Jaipur, and Lucknow; separate in-depth interviews
with 10 physicians.
Epidemiology: Prevalence of CaB: total diagnosed incident cases
in urban and rural India; ten-year epidemiology forecasts through 2017.
Market forecast features: Our analysis evaluates the
size of the population with access to medical care and rates of treatment with
hormone therapy and chemotherapy agents. We include a detailed forecast for CaB
drug classes and leading brands for 2007-2012, using a combination of
historical trend analysis and an epidemiology-based, bottom-up market model.